What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in CHI3L1, study by study
1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Oral sodium phenylbutyrate and taurursodiol combination for 24 weeks in people with amyotrophic lateral sclerosis | Plasma YKL-40 geometric LS mean about 20% lower than placebo at week 24 (p=0.008); CRP -30% | RCT | Bowser R, et al. J Neurol Neurosurg Psychiatry. 2024. Effect of sodium… |
Sources
- See the catalogue entry in the research dashboard.
Related markers: Alpha-1-Antichymotrypsin (AACT) · Alpha-1-Antitrypsin (AAT) · Antinuclear Antibodies (ANA) · CD4:CD8 T-Cell Ratio · CD8+ T-Cell Count · Erythrocyte Sedimentation Rate (ESR) · Fibrinogen · Growth Differentiation Factor-15 (GDF-15)